Clinical trial results with MPA/E 2C

L. P. Shulman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Results of a multicenter, controlled U.S. trial that evaluated a new monthly combination injectable have confirmed that the injectable formulation is both highly effective and well tolerated. The results of the U.S. trial are consistent with clinical studies conducted in other countries by the WHO and suggest that this new contraceptive method will expand clinical options for preventing pregnancy. The specific advantages of the monthly injectable formulation include infrequent dosing, rapid reversibility and a degree of efficacy that rivals sterilization.

Original languageEnglish (US)
Pages (from-to)873-877
Number of pages5
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Issue number10 SUPPL.
StatePublished - Nov 15 2000


  • Combination injectable contraceptives
  • Contraceptive agents, female
  • Contraceptives, oral, hormonal
  • MPA/E C

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine


Dive into the research topics of 'Clinical trial results with MPA/E <sub>2</sub>C'. Together they form a unique fingerprint.

Cite this